Use of liposomal anthracyclines in Kaposi's sarcoma

Susan E. Krown, Donald W Northfelt, David Osoba, J. Simon Stewart

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.

Original languageEnglish (US)
Pages (from-to)36-52
Number of pages17
JournalSeminars in Oncology
Volume31
Issue numberSUPPL. 13
DOIs
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Kaposi's Sarcoma
Anthracyclines
Bleomycin
Vincristine
liposomal doxorubicin
Doxorubicin
Liposomes
Hand-Foot Syndrome
Drug Therapy
Stomatitis
Daunorubicin

ASJC Scopus subject areas

  • Oncology

Cite this

Use of liposomal anthracyclines in Kaposi's sarcoma. / Krown, Susan E.; Northfelt, Donald W; Osoba, David; Stewart, J. Simon.

In: Seminars in Oncology, Vol. 31, No. SUPPL. 13, 12.2004, p. 36-52.

Research output: Contribution to journalArticle

Krown, Susan E. ; Northfelt, Donald W ; Osoba, David ; Stewart, J. Simon. / Use of liposomal anthracyclines in Kaposi's sarcoma. In: Seminars in Oncology. 2004 ; Vol. 31, No. SUPPL. 13. pp. 36-52.
@article{e91c63723ad74aaa8a552016de1f47e0,
title = "Use of liposomal anthracyclines in Kaposi's sarcoma",
abstract = "Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.",
author = "Krown, {Susan E.} and Northfelt, {Donald W} and David Osoba and Stewart, {J. Simon}",
year = "2004",
month = "12",
doi = "10.1053/j.seminoncol.2004.08.003",
language = "English (US)",
volume = "31",
pages = "36--52",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 13",

}

TY - JOUR

T1 - Use of liposomal anthracyclines in Kaposi's sarcoma

AU - Krown, Susan E.

AU - Northfelt, Donald W

AU - Osoba, David

AU - Stewart, J. Simon

PY - 2004/12

Y1 - 2004/12

N2 - Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.

AB - Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.

UR - http://www.scopus.com/inward/record.url?scp=11144301724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144301724&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2004.08.003

DO - 10.1053/j.seminoncol.2004.08.003

M3 - Article

C2 - 15717737

AN - SCOPUS:11144301724

VL - 31

SP - 36

EP - 52

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 13

ER -